Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1993 May;48(5):547–553. doi: 10.1136/thx.48.5.547

Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism.

A Lindén 1, A Bergendal 1, A Ullman 1, B E Skoogh 1, C G Löfdahl 1
PMCID: PMC464514  PMID: 8100652

Abstract

BACKGROUND--Formoterol and salmeterol are new long acting beta 2 adrenoceptor agonists. The maximum relaxant effect, potency and functional antagonism against carbachol induced contraction for salmeterol, formoterol and salbutamol have been compared in the guinea pig isolated trachea. In addition, the possibility of inducing a non-beta adrenoceptor mediated relaxation by salmeterol was studied. METHODS--Concentration response experiments were conducted with isolated tracheal preparations (n = 4-6 in all experiments), precontracted by carbachol to cause either 40% (60 nmol/l), 80% (0.3 mumol/l) or 100% (3 mumol/l, supramaximal) of the maximum contraction. Each beta agonist was added cumulatively at each level of precontraction. Additional cumulative concentration response experiments were conducted for salmeterol alone at the highest level of precontraction, with and without beta blockade by sotalol (1 mmol/l). With the drug concentrations which produced the maximum response and the highest level of precontraction, the relaxation of formoterol (10 nmol/l) and salmeterol (1 mumol/l) was also compared non-cumulatively. Finally, with the corresponding drug concentrations and precontraction, the relaxant effect was compared for formoterol (10 nmol/l) in salmeterol relaxed airways with that of salmeterol (1 mumol/l) in formoterol relaxed airways. RESULTS--The increase in carbachol concentration from 60 nmol/l to 3 mumol/l induced a rightward shift in the mean (SE) concentration (log steps) causing 50% maximum relaxation for salmeterol (0.73 (0.17)), formoterol (0.85 (0.18)), and salbutamol (1.13 (0.11)). Significant differences in the maximum relaxant effect were shown at the highest level of precontraction only, with a remaining active tension of percentage precontraction of 27% (4%) for 1 mumol/l salbutamol and 35% (3%) for 10 nmol/l formoterol compared with 50% (2%) for 1 mumol/l salmeterol. The rank order of potency was: formoterol > salbutamol approximately salmeterol at all levels of precontraction (-log EC50: 9.32 (0.05) for formoterol, 7.82 (0.08) for salbutamol, and 7.50 (0.13) for salmeterol at 80% maximum precontraction). Beta blockade by sotalol (1 mmol/l) significantly inhibited the relaxation induced by salmeterol (1 mumol/l) (remaining active tension: 104% (1%) v 71% (11%) of precontraction) but not the relaxation induced by salmeterol (10 mumol/l) (remaining active tension: 75% (5%) v 71% (12%) of precontraction). In the non-cumulative experiments, formoterol displayed more relaxant effect than salmeterol (remaining active tension: 51% (6%) v 65% (6%) of precontraction). Finally, formoterol significantly relaxed salmeterol relaxed airways (relaxant effect: 22% (8%) of precontraction) whereas there was no significant response to salmeterol in formoterol relaxed airways (relaxant effect: 5% (12%) of precontraction). CONCLUSIONS--In the guinea pig isolated trachea, formoterol and salbutamol produce more relaxant effect than salmeterol, suggesting that salmeterol is a partial beta 2 agonist. Very high concentrations of salmeterol may induce non-beta adrenoceptor mediated relaxation. Formoterol is more potent than both salbutamol and salmeterol. There is no pronounced difference in the magnitude of antagonism against carbachol induced contractions between salmeterol, formoterol, and salbutamol.

Full text

PDF
547

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arvidsson P., Larsson S., Löfdahl C. G., Melander B., Svedmyr N., Wåhlander L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J. 1991 Nov;4(10):1168–1173. [PubMed] [Google Scholar]
  2. Arvidsson P., Larsson S., Löfdahl C. G., Melander B., Wåhlander L., Svedmyr N. Formoterol, a new long-acting bronchodilator for inhalation. Eur Respir J. 1989 Apr;2(4):325–330. [PubMed] [Google Scholar]
  3. Ball D. I., Brittain R. T., Coleman R. A., Denyer L. H., Jack D., Johnson M., Lunts L. H., Nials A. T., Sheldrick K. E., Skidmore I. F. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol. 1991 Nov;104(3):665–671. doi: 10.1111/j.1476-5381.1991.tb12486.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beach J. R., Young C. L., Stenton S. C., Avery A. J., Walters E. H., Hendrick D. J. A comparison of the speeds of action of salmeterol and salbutamol in reversing methacholine-induced bronchoconstriction. Pulm Pharmacol. 1992 Jun;5(2):133–135. doi: 10.1016/0952-0600(92)90031-b. [DOI] [PubMed] [Google Scholar]
  5. Decker N., Quennedey M. C., Rouot B., Schwartz J., Velly J. Effects of N-aralkyl substitution of beta-agonists on alpha- and beta-adrenoceptor subtypes: pharmacological studies and binding assays. J Pharm Pharmacol. 1982 Feb;34(2):107–112. doi: 10.1111/j.2042-7158.1982.tb04195.x. [DOI] [PubMed] [Google Scholar]
  6. Dreyer A. C., Offermeier J. In vitro assessment of the selectivities of various beta-adrenergic blocking agents. Life Sci. 1980 Dec 1;27(22):2087–2092. doi: 10.1016/0024-3205(80)90489-0. [DOI] [PubMed] [Google Scholar]
  7. Jeppsson A. B., Johansson U., Waldeck B. Dissociation between the effects of some xanthine derivatives on the tracheal smooth muscle and on the skeletal muscle. Acta Pharmacol Toxicol (Copenh) 1982 Aug;51(2):115–121. doi: 10.1111/j.1600-0773.1982.tb01000.x. [DOI] [PubMed] [Google Scholar]
  8. Jeppsson A. B., Källström B. L., Waldeck B. Studies on the interaction between formoterol and salmeterol in guinea-pig trachea in vitro. Pharmacol Toxicol. 1992 Oct;71(4):272–277. doi: 10.1111/j.1600-0773.1992.tb00982.x. [DOI] [PubMed] [Google Scholar]
  9. Jeppsson A. B., Löfdahl C. G., Waldeck B., Widmark E. On the predictive value of experiments in vitro in the evaluation of the effect duration of bronchodilator drugs for local administration. Pulm Pharmacol. 1989;2(2):81–85. doi: 10.1016/0952-0600(89)90028-8. [DOI] [PubMed] [Google Scholar]
  10. Kerrebijn K. F. Long-term drug treatment of asthma in children. Lung. 1990;168 (Suppl):142–153. doi: 10.1007/BF02718127. [DOI] [PubMed] [Google Scholar]
  11. Lindén A., Löfdahl C. G., Ullman A., Skoogh B. E. In vitro characteristics of spontaneous airway tone in the guinea-pig. Acta Physiol Scand. 1991 Jul;142(3):351–357. doi: 10.1111/j.1748-1716.1991.tb09168.x. [DOI] [PubMed] [Google Scholar]
  12. Lindén A., Ullman A., Skoogh B. E., Löfdahl C. G. Non-adrenergic, non-cholinergic regulation of guinea-pig airway smooth muscle-indomethacin-induced changes and segmental differences. Pulm Pharmacol. 1991;4(3):170–176. doi: 10.1016/0952-0600(91)90008-q. [DOI] [PubMed] [Google Scholar]
  13. Löfdahl C. G., Svedmyr N. Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy. 1989 May;44(4):264–271. doi: 10.1111/j.1398-9995.1989.tb01068.x. [DOI] [PubMed] [Google Scholar]
  14. Maesen F. P., Smeets J. J., Gubbelmans H. L., Zweers P. G. Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours. Chest. 1990 Mar;97(3):590–594. doi: 10.1378/chest.97.3.590. [DOI] [PubMed] [Google Scholar]
  15. Malo J. L., Cartier A., Trudeau C., Ghezzo H., Gontovnick L. Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. Am Rev Respir Dis. 1990 Nov;142(5):1147–1152. doi: 10.1164/ajrccm/142.5.1147. [DOI] [PubMed] [Google Scholar]
  16. Sykes A. P., Ayres J. G. A study of the duration of the bronchodilator effect of 12 micrograms and 24 micrograms of inhaled formoterol and 200 micrograms inhaled salbutamol in asthma. Respir Med. 1990 Mar;84(2):135–138. doi: 10.1016/s0954-6111(08)80016-9. [DOI] [PubMed] [Google Scholar]
  17. Torphy T. J., Rinard G. A., Rietow M. G., Mayer S. E. Functional antagonism in canine tracheal smooth muscle: inhibition by methacholine of the mechanical and biochemical responses to isoproterenol. J Pharmacol Exp Ther. 1983 Dec;227(3):694–699. [PubMed] [Google Scholar]
  18. Ullman A., Bergendal A., Lindén A., Waldeck B., Skoogh B. E., Löfdahl C. G. Onset of action and duration of effect of formoterol and salmeterol compared to salbutamol in isolated guinea pig trachea with or without epithelium. Allergy. 1992 Aug;47(4 Pt 2):384–387. doi: 10.1111/j.1398-9995.1992.tb02076.x. [DOI] [PubMed] [Google Scholar]
  19. Ullman A., Ciabattoni G., Löfdahl C. G., Lindén A., Svedmyr N., Skoogh B. E. Epithelium-derived PGE2 inhibits the contractile response to cholinergic stimulation in isolated ferret trachea. Pulm Pharmacol. 1990;3(3):155–160. doi: 10.1016/0952-0600(90)90047-m. [DOI] [PubMed] [Google Scholar]
  20. Ullman A., Svedmyr N. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax. 1988 Sep;43(9):674–678. doi: 10.1136/thx.43.9.674. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES